These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 29460668)

  • 41. State criminal justice policy context and opioid agonist treatment delivery among opioid treatment admissions, 2015.
    Mantha S; Mauro PM; Mauro CM; Martins SS
    Drug Alcohol Depend; 2020 Jan; 206():107654. PubMed ID: 31735533
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Methadone, buprenorphine and preferences for opioid agonist treatment: A qualitative analysis.
    Yarborough BJ; Stumbo SP; McCarty D; Mertens J; Weisner C; Green CA
    Drug Alcohol Depend; 2016 Mar; 160():112-8. PubMed ID: 26796596
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Characteristics and current clinical practices of opioid treatment programs in the United States.
    Jones CM; Byrd DJ; Clarke TJ; Campbell TB; Ohuoha C; McCance-Katz EF
    Drug Alcohol Depend; 2019 Dec; 205():107616. PubMed ID: 31678836
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Medication-assisted treatment for opioid use disorder within a 12-step based treatment center: Feasibility and initial results.
    Klein AA; Seppala MD
    J Subst Abuse Treat; 2019 Sep; 104():51-63. PubMed ID: 31370985
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Opioid Agonist Treatment Recipients within Criminal Justice-Involved Populations.
    Guastaferro WP; Koetzle D; Lutgen-Nieves L; Teasdale B
    Subst Use Misuse; 2022; 57(5):698-707. PubMed ID: 35172673
    [No Abstract]   [Full Text] [Related]  

  • 46. Pharmacological interventions for drug-using offenders.
    Perry AE; Neilson M; Martyn-St James M; Glanville JM; McCool R; Duffy S; Godfrey C; Hewitt C
    Cochrane Database Syst Rev; 2013 Dec; (12):CD010862. PubMed ID: 24353217
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Extended-release injectable naltrexone for opioid use disorder: a systematic review.
    Jarvis BP; Holtyn AF; Subramaniam S; Tompkins DA; Oga EA; Bigelow GE; Silverman K
    Addiction; 2018 Jul; 113(7):1188-1209. PubMed ID: 29396985
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of a jail-based treatment decision-making intervention on post-release initiation of medications for opioid use disorder.
    Banta-Green CJ; Williams JR; Sears JM; Floyd AS; Tsui JI; Hoeft TJ
    Drug Alcohol Depend; 2020 Feb; 207():107799. PubMed ID: 31865058
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Diagnosis and Management of Opioid Use Disorder in Hospitalized Patients.
    Herscher M; Fine M; Navalurkar R; Hirt L; Wang L
    Med Clin North Am; 2020 Jul; 104(4):695-708. PubMed ID: 32505261
    [TBL] [Abstract][Full Text] [Related]  

  • 50. An ethical analysis of medication treatment for opioid use disorder (MOUD) for persons who are incarcerated.
    Brezel ER; Powell T; Fox AD
    Subst Abus; 2020; 41(2):150-154. PubMed ID: 31800376
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Developing an index to measure the voluntariness of consent to research.
    Dugosh KL; Festinger DS; Marlowe DB; Clements NT
    J Empir Res Hum Res Ethics; 2014 Oct; 9(4):60-70. PubMed ID: 25747297
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence: A Randomized Clinical Noninferiority Trial.
    Tanum L; Solli KK; Latif ZE; Benth JŠ; Opheim A; Sharma-Haase K; Krajci P; Kunøe N
    JAMA Psychiatry; 2017 Dec; 74(12):1197-1205. PubMed ID: 29049469
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Extended-release naltrexone for pre-release prisoners: A randomized trial of medical mobile treatment.
    Gordon MS; Vocci FJ; Fitzgerald TT; O'Grady KE; O'Brien CP
    Contemp Clin Trials; 2017 Feb; 53():130-136. PubMed ID: 28011389
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cost-effectiveness of extended-release injectable naltrexone among incarcerated persons with opioid use disorder before release from prison versus after release.
    Jalali A; Jeng PJ; Polsky D; Poole S; Ku YC; Woody GE; Murphy SM
    J Subst Abuse Treat; 2022 Oct; 141():108835. PubMed ID: 35933942
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Psychosocial factors in outcome in two opiate addiction treatments.
    Grey C; Osborn E; Reznikoff M
    J Clin Psychol; 1986 Jan; 42(1):185-9. PubMed ID: 3950006
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Exploring the Concepts of Abstinence and Recovery Through the Experiences of Long-Term Opiate Substitution Clients.
    Notley C; Blyth A; Maskrey V; Pinto H; Holland R
    Subst Abus; 2015; 36(2):232-9. PubMed ID: 25127184
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evidence-based treatment and supervision practices for co-occurring mental and substance use disorders in the criminal justice system.
    Peters RH; Young MS; Rojas EC; Gorey CM
    Am J Drug Alcohol Abuse; 2017 Jul; 43(4):475-488. PubMed ID: 28375656
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Healthcare utilization in adults with opioid dependence receiving extended release naltrexone compared to treatment as usual.
    Soares WE; Wilson D; Rathlev N; Lee JD; Gordon M; Nunes EV; O'Brien CP; Friedmann PD
    J Subst Abuse Treat; 2018 Feb; 85():66-69. PubMed ID: 28576389
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy of Tramadol Extended-Release for Opioid Withdrawal: A Randomized Clinical Trial.
    Dunn KE; Tompkins DA; Bigelow GE; Strain EC
    JAMA Psychiatry; 2017 Sep; 74(9):885-893. PubMed ID: 28700791
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A randomized, double-blind evaluation of buprenorphine taper duration in primary prescription opioid abusers.
    Sigmon SC; Dunn KE; Saulsgiver K; Patrick ME; Badger GJ; Heil SH; Brooklyn JR; Higgins ST
    JAMA Psychiatry; 2013 Dec; 70(12):1347-54. PubMed ID: 24153411
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.